Fate Therapeutics (FATE) Misses Q3 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/31/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. GILD
9. SBUX
10. SNDK

Go back to Fate Therapeutics (FATE) Misses Q3 EPS by 6c

Fate Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Operational Progress

November 1, 2018 4:01 PM EDT

Twenty Subjects Treated across Three Phase 1 Studies of FATE-NK100

Entered into Off-the-Shelf, iPSC-derived CAR-T Cell Collaboration with ONO Pharmaceutical

Completed $144M Common Stock Public Offering

Three Oral and Four Poster Presentations Covering Product Pipeline will be Presented at ASH Annual Meeting

SAN DIEGO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today reported business... More